Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05143073 · ClinicalTrials.gov registry record · NA
Understanding Genetic Risk for Alcohol Use Disorder
A NA study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- NA
- Development phase
- 338
- Enrollment target
NCT05143073: Completed NA study, sponsored by Virginia Commonwealth University.
NCT05143073 is a NA study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 338 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05143073, a NA study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- NA
- Development phase
- 338 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate an online educational tool that will help individuals better understand alcohol use disorder, risk factors, and genetic risk information and to better understand participant's beliefs regarding alcohol use disorder. This study does not involve genetic testing. Investigators will not be giving participants any personalized genetic feedback as part of the study; however, investigators will ask participants to imagine that they receive different hypothetical genetic risk scores and respond to survey items.
Primary Outcome
Understanding of genetic risk scores for alcohol use disorder will be assessed after each of the three hypothetical scenarios in which participants receive a low genetic risk score, average genetic risk score, and high genetic risk score. Participants will respond to a series of true/false/don't know statements to assess understanding and interpretation of each genetic risk score. Responses will be scored as correct or incorrect and summed to create an overall score.
Interventions
- BEHAVIORAL Alcohol use disorder and strategies to reduce risk educational material
- BEHAVIORAL Complex polygenic risk scores, alcohol use disorder, and strategies to reduce risk educational material
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2021-11-15 |
| Est. Completion | 2021-12-13 |
| Phase | NA |
What the finished NCT05143073 record still lists
NCT05143073 is an interventional study that assigns participants to a tested intervention. The registered 338 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 2 interventions - of which Alcohol use disorder and strategies to reduce risk educational material is the first listed.
NCT05143073 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05143073 about?
NCT05143073 is a clinical study titled "Understanding Genetic Risk for Alcohol Use Disorder". The purpose of this study is to evaluate an online educational tool that will help individuals better understand alcohol use disorder, risk factors, and genetic risk information and to better understand participant's beliefs regarding alcohol use disorder. This study does not involve genetic testing...
What is the current status of trial NCT05143073?
This trial is currently completed. It is a NA study. The enrollment target is 338 participants. The study started on 2021-11-15. Estimated completion is 2021-12-13.
What interventions are being tested in trial NCT05143073?
The interventions under investigation include: Alcohol use disorder and strategies to reduce risk educational material (BEHAVIORAL), Complex polygenic risk scores, alcohol use disorder, and strategies to reduce risk educational material (BEHAVIORAL).
Who is sponsoring clinical trial NCT05143073?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05143073's enrollment target sits among peer trials
338 305th of 2000 higher than 1,696 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03253263 · 338 participants · Phase 2
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
- NCT05658731 · 338 participants · NA
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
- NCT06022939 · 338 participants · Phase 3
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
- NCT04176172 · 340 participants · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI